Please use this identifier to cite or link to this item:
https://archive.cm.mahidol.ac.th/handle/123456789/5473Full metadata record
| DC Field | Value | Language |
|---|---|---|
| eperson.contributor.advisor | Simon M. Zaby | - |
| dc.contributor.author | Variya Nithiuthai | - |
| dc.date.accessioned | 2024-09-04T08:17:01Z | - |
| dc.date.available | 2024-09-04T08:17:01Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.other | TP FM.027 2023 | - |
| dc.identifier.uri | https://archive.cm.mahidol.ac.th/handle/123456789/5473 | - |
| dc.description | 58 leaves | en_US |
| dc.description.abstract | This thematic paper explores the intrinsic value of Pfizer Inc. (PFE) share price by using the discounted cash flow valuation method (DCF) to assess if a stock is overvalued or undervalued to empower investors to navigate the market more effectively. According to the DCF analysis in this paper, the implied share value of Pfizer is $48.96 per share, which is 39% higher than the latest stock price as of November 10, 2023. This suggests that Pfizer’s intrinsic value is higher than its market price, and the current price of $29.68 per share is undervalued. Hence, the recommendation is to “BUY” | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Mahidol University | en_US |
| dc.subject | Corporate Finance | en_US |
| dc.subject | Pfizer | en_US |
| dc.subject | PFE | en_US |
| dc.subject | Valuation | en_US |
| dc.subject | Discounted cash flow valuation (DCF) | en_US |
| dc.subject | Phamaceuticals | en_US |
| dc.title | Discounted cash flow valuation of prizer inc. | en_US |
| dc.type | Thesis | en_US |
| Appears in Collections: | Thematic Paper | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| TP FM.027 2023.pdf | 2.42 MB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.